Woburn, MA. – August 23, 2022 – Aphios Pharma, a herbal medicine developer focused on treating central and peripheral nervous system disorders such as anxiety, cancer pain or multiple sclerosis (MS) and opioid use disorders without the use of opioids, has raised over $90,000 in capital a crowdfunding campaign by Wefund. This green biotech company uses nano-encapsulation in its delivery method, is valued at $70 million, and has an initial investment of $250.

Herbal therapeutic edibles and inhalants have been used for decades to relieve pain without opioids or other prescription drugs. However, they are only partially effective because they consist of a combination of compounds that are not specific to the disease. In addition, they have a shorter duration of action because they move quickly through the body. Unlike the traditional means of using herbal therapeutics to treat pain — and anxiety — Aphios Pharma uses a proprietary approach.

“Most often, herbal therapeutics work for anxiety, chronic pain, opioid use disorders, anxiety, and multiple sclerosis, but only acutely because they are smoked or ingested. Herbal therapeutics work only partially because they are usually mixtures of many compounds that are nonspecific to the disease, and only acutely because they are like olive oil that goes straight through the body when ingested or smoked,” said Dr. Trevor P. Castor, President and CEO of Aphios Pharma, LLC.

“Our value proposition is that we develop specific cannabinoids for certain diseases and deliver them in patented, proprietary nanoparticles to control their release in the body and maintain their effectiveness in chronic diseases.” Castor adds.

Endocannabinoids are naturally occurring molecules that help your body function efficiently and your nervous system stay in balance. Endocannabinoids can become imbalanced when adverse health events such as pain or anxiety occur. Aphios…